Promising Pharmaceutical Stocks To Consider – November 9th

Eli Lilly and Company, AbbVie, Johnson & Johnson, Pfizer, and Merck & Co., Inc. are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares in publicly traded companies that research, develop, manufacture, or sell medicines. For investors, their value can be affected by factors such as clinical-trial results, regulatory approvals, patent protection, competition, and drug sales. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Eli Lilly and Company stock traded up $50.69 during trading on Monday, reaching $1,404.69. The stock had a trading volume of 1,281,247 shares, compared to its average volume of 2,955,723. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,453.00. The business has a 50 day moving average price of $1,215.24 and a 200 day moving average price of $1,101.16. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The stock has a market cap of $1.32 trillion, a PE ratio of 45.55, a P/E/G ratio of 1.62 and a beta of 0.40.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded up $1.79 during trading hours on Monday, reaching $293.10. The stock had a trading volume of 1,957,512 shares, compared to its average volume of 6,327,668. AbbVie has a 1 year low of $190.75 and a 1 year high of $302.93. The firm’s 50 day moving average is $271.98 and its 200-day moving average is $239.04. The stock has a market capitalization of $518.09 billion, a price-to-earnings ratio of 50.47, a P/E/G ratio of 1.32 and a beta of 0.20.

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Shares of Johnson & Johnson stock traded up $5.25 during trading on Monday, hitting $281.47. 1,990,135 shares of the stock were exchanged, compared to its average volume of 7,947,287. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The firm’s 50-day moving average price is $265.91 and its 200 day moving average price is $248.30. The stock has a market cap of $677.59 billion, a price-to-earnings ratio of 42.61, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.02.

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

NYSE PFE traded up $0.07 during trading on Monday, reaching $29.46. 15,388,718 shares of the company’s stock were exchanged, compared to its average volume of 39,817,813. The company has a 50 day moving average price of $28.74 and a two-hundred day moving average price of $26.90. The stock has a market cap of $167.95 billion, a P/E ratio of 42.05, a price-to-earnings-growth ratio of 1.93 and a beta of 0.31. Pfizer has a 1 year low of $23.62 and a 1 year high of $31.44. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42.

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of NYSE MRK traded up $1.11 during midday trading on Monday, hitting $147.84. 2,091,214 shares of the company’s stock were exchanged, compared to its average volume of 10,610,717. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. Merck & Co., Inc. has a twelve month low of $85.80 and a twelve month high of $156.92. The company has a market cap of $364.47 billion, a PE ratio of 152.37, a P/E/G ratio of 6.68 and a beta of 0.13. The firm’s fifty day simple moving average is $146.39 and its 200-day simple moving average is $127.63.